Non-myeloablative regimen consisting of busulfan, fludarabine, and ATG for allogeneic peripheral blood stem cell transplantation.

被引：0
|
作者：
Mayer, J [1 ]
Koristek, Z [1 ]
Krahulová, M [1 ]
Vorlicek, J [1 ]
机构：
[1] Masaryk Univ Hosp, Brno, Czech Republic
来源：
EXPERIMENTAL HEMATOLOGY | 1999年 / 27卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
361
引用
收藏
页码：131 / 131
页数：1
相关论文
共 50 条
  • [1] Allogeneic PBSC transplantation after non-myeloablative regimen containing busulfan, fludarabine, and ATG.
    Mayer, J
    Krahulová, M
    Korístek, Z
    Vorlícek, J
    BONE MARROW TRANSPLANTATION, 1999, 23 : S23 - S23
  • [2] Allogenic PBSC transplantation after non-myeloablative regimen containing busulfan, fludarabine, and ATG
    Mayer, J
    Krahulova, M
    Koristek, Z
    Dvorakova, D
    Brychtova, Y
    Doubek, M
    BONE MARROW TRANSPLANTATION, 2001, 27 : S289 - S290
  • [3] Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation
    Lee, KH
    Lee, JH
    Lee, JH
    Kim, WK
    Chi, HS
    Lee, JS
    HAEMATOLOGICA, 2001, 86 (09) : 999 - 1001
  • [4] Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation.
    Mackinnon, S
    Kottaridis, P
    Perry, A
    Chakrabarti, S
    Milligan, DW
    Pettengell, R
    Chopra, R
    Morgan, G
    Hale, G
    Waldmann, H
    Linch, DC
    Devereux, S
    Goldstone, AH
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 : 31 - 31
  • [5] Treatment of multiple myeloma with an allogeneic peripheral blood stem cell transplantation using a non-myeloablative conditioning regimen
    Kmonicek, M
    Zak, P
    Jebavy, L
    Maisnar, V
    Maly, J
    BONE MARROW TRANSPLANTATION, 2003, 31 : S86 - S86
  • [6] Allogeneic peripheral blood stem cell transplantation using a non-myeloablative conditioning regimen for malignant lymphoma.
    Nagler, A
    Or, R
    Naparstek, E
    Varadi, G
    Slavin, S
    BONE MARROW TRANSPLANTATION, 1999, 23 : S23 - S23
  • [7] Allogeneic PBSC transplantation after a non-myeloablative regimen containing fludarabine, busulfan, and ATG: low TRM and good anti-tumor activity
    Mayer, J
    Doubek, M
    Koristek, Z
    Krejci, M
    Brychtova, Y
    Navratil, M
    Vasova, I
    Tomiska, M
    Buchtova, I
    BONE MARROW TRANSPLANTATION, 2003, 31 : S146 - S146
  • [8] Fludarabine/cyclophosphamide non-myeloablative allogeneic stem cell transplantation for lymphoid malignancies
    Auer, R. L.
    MacDougall, F.
    Oakervee, H. E.
    Cavenagh, J. C.
    Gribben, J. G.
    Lister, T. A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 70 - 70
  • [9] Progressive disease after non-myeloablative allogeneic stem cell transplantation.
    Bolwell, BJ
    Pohlman, B
    Sobecks, R
    Andresen, S
    Theil, KS
    Brown, S
    Bernhard, L
    Curtis, J
    Koennecke, J
    Kosar, J
    Ostendorf, H
    Sands, K
    Serafin, M
    Kalaycio, M
    BLOOD, 2002, 100 (11) : 634A - 634A
  • [10] Fludarabine/Cyclophosphamide/Rituxan is an effective regimen for non-myeloablative allogeneic stem cell transplantation (SCT) for lymphoid malignancies.
    Berkahn, LC
    Simpson, DR
    Raptis, A
    Klingemann, HG
    BLOOD, 2000, 96 (11) : 352B - 352B
12345